Publicacións en colaboración con investigadores/as de Beckman Research Institute (34)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 113, Núm. 5, pp. 593-605

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

  5. Genome-Wide Gene-Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 33, Núm. 3, pp. 400-410

  6. Identifying major histocompatibility complex class II-DR molecules in bovine and swine peripheral blood monocyte-derived macrophages using mAb-L243

    Vaccine, Vol. 42, Núm. 15, pp. 3445-3454

  7. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

  8. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  2. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

  3. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

  4. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. A clinico-pathological and molecular analysis reveals differences between solitary (early and late-onset) and synchronous rectal cancer

    Scientific Reports, Vol. 11, Núm. 1

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  4. NAIP expression increases in a rat model of liver mass restoration

    Journal of Molecular Histology, Vol. 52, Núm. 1, pp. 113-123

  5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

2020

  1. Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer

    Gastroenterology, Vol. 158, Núm. 5, pp. 1274-1286.e12